Should you buy Century Therapeutics stock now?
The technical signal for Century Therapeutics is currently NEUTRAL. Century Therapeutics trades at $1.98 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -0.075 with falling momentum (signal: -0.056); RSI is at 38.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $4.75 points to 139.9% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Century Therapeutics stock?
The average analyst price target for Century Therapeutics is $4.75. The current price is $1.98, which gives an upside of 139.9%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $4.28 and $5.23.
Is Century Therapeutics a dividend stock?
No, Century Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Century Therapeutics stock?
Century Therapeutics is rated as a stock with extreme risk. the annual standard deviation is 97.1%, which classifies the stock as extreme risk.
Is Century Therapeutics overvalued?
No, Century Therapeutics is considered undervalued based on the analyst price target (139.9% upside). Century Therapeutics has the following valuation ratios: a P/S ratio of 3.7, a P/B ratio of 1.4. The analyst price target suggests that the stock is undervalued by 139.9%.
Is Century Therapeutics overbought?
No, Century Therapeutics is not overbought. RSI is at 38.7 (neutral zone). The technical indicators show: RSI is at 38.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.3% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Century Therapeutics earnings report?
Century Therapeutics reports its next earnings on August 13, 2026. The stock currently trades at $1.98.
Is Century Therapeutics shorted?
Yes, Century Therapeutics is shorted with 15.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Century Therapeutics stock?
No, insiders are not buying Century Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 8 sales. On a net basis, 116,834 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 367,135 $ sold. Active sellers include Russotti Gregory, Carr Douglas, Pfeiffenberger Brent and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Century Therapeutics a good stock?
Based on our total score, Century Therapeutics is rated as a poor stock with a total score of 25 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 35/100, Quality: 8/100, Momentum: 33/100. In addition: analysts see 139.9% upside to the price target; technical signal: Hold. Whether Century Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Century Therapeutics stock?
The outlook for Century Therapeutics based on current data: the average analyst price target is $4.75 (+139.9%); the next earnings report is due on 8/13/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Century Therapeutics stock falling?
Century Therapeutics is falling right now. The technical indicators show: the price is 7.3% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 15.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Century Therapeutics go?
The average analyst price target for Century Therapeutics is $4.75, which corresponds to a potential gain of 139.9% from the current price of $1.98. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Century Therapeutics fall?
We lack enough history to give a specific floor for Century Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Century Therapeutics do?
Century Therapeutics udvikler allogene celleterapier, der skal behandle solide tumorer, blodsygdomme og autoimmune lidelser. De specialiserer sig i at bruge iPSCs (inducerede pluripotente stamceller) til at lave de her behandlinger. Deres hovedprodukt, CNTY-101, er en CAR-iNK ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Century Therapeutics as an investment.
Did Century Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Century Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Century Therapeutics making money or losing money?
We have no current profitability data for Century Therapeutics. See the latest report in the earnings history above.
Can Century Therapeutics go bankrupt?
The bankruptcy risk of Century Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -3.22 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 119% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Century Therapeutics have a lot of debt?
Century Therapeutics has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 119%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
